In the US, Eptifibatide (eptifibatide systemic) is a member of the drug class glycoprotein platelet inhibitors and is used to treat Acute Coronary Syndrome, Angina, Heart Attack and Percutaneous Coronary Intervention.
- Eptifibatide Accord
- EPTIFIBATIDE 0.75 MG/ML SOLUTION FOR INFUSION (Leaflet)
- EPTIFIBATIDE 2 MG/ML SOLUTION FOR INJECTION (Leaflet)
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Antiplatelet agent: Glycoprotein IIb/IIIa-receptor antagonist
Cyclo(S-S)-mercaptopropionyl-(L) homoarginyl-glycyl-(L) aspartyl-(L) tryptophanyl-(L) prolyl-(L) cysteinamide
- Eptifibatidum (Latin)
- Eptifibatid (German)
- Eptifibatide (French)
- Eptifibatida (Spanish)
- Eptifibatide (OS: DCF, BAN)
- C 6822 (IS)
- Intrifiban (IS)
- SB 1 (IS)
- SCH 60936 (IS)
- Eptifibatide Strides
Agila, Bulgaria; Strides Arcolab, Poland
- Eptifibatide Teva
Glaxo Group, Austria; Glaxo Group, Hungary; Glaxo Group, Iceland; Glaxo Group, Poland; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Spain; GlaxoSmithKline, Finland; GlaxoSmithKline, Greece; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Ireland; GlaxoSmithKline, Italy; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Norway; GlaxoSmithKline, Portugal; GlaxoSmithKline, Romania; GlaxoSmithKline, Serbia; GlaxoSmithKline, Slovakia; GlaxoSmithKline Laboratoire Pharmaceutique, France; GlaxoSmithKline UK, United Kingdom; GSK, Belgium; Merck, Canada; Merck Sharp & Dohme, Hong Kong; Merck Sharp & Dohme, New Zealand; MSD, Thailand; Schering, United States; Schering-Plough, Argentina; Schering-Plough, Indonesia; Schering-Plough, Israel; Schering-Plough, Taiwan; Schering-Plough, South Africa; Scherring, Egypt
|BAN||British Approved Name|
|DCF||Dénomination Commune Française|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.